U.S. BENIGN UTERINE CONDITIONS THERAPY SYSTEMS MARKET

151 Pages | 53 Exhibits | 2013 Analysis | Forecasts Through 2017

OVERVIEW:
The U.S. market for therapy systems for the treatment of benign uterine conditions has grown significantly over the past decade, reaching nearly $600 million in 2012. This growing medical device market-which includes: global endometrial ablation (GEA) devices, uterine artery embolization (UAE) systems, hysteroscopes and related products, as well as new and innovative single-insertion hysteroscopic morcellator systems-is expected to expand at a healthy compound annual growth rate of approximately 3.8%, growing by more than $100 million over a span of 5 years.

As with many other markets for medical devices, therapy systems for benign uterine conditions have been negatively impacted by the economic recession and resultant loss of employment/income and subsequent postponement of elective procedures among potential patients. Despite a sluggish economy, however, growth in this segment is expected to accelerate at a low to moderate pace throughout the forecast period, as the market benefits from continued favorable clinical outcomes and the adoption of next-generation therapy systems or instruments that facilitate minimally invasive options and/or safer, more effective, cost-effective treatment of benign uterine conditions. Despite the implementation of the medical device excise tax and reimbursement/pricing challenges, healthcare reform and an increase in the covered female patient population is expected to trend to less invasive/costly options such as hysteroscopic resection and GEA procedures. This market may experience a significant increase in procedures near the end of the forecast period covered by this report (should the economy rebound) due to pent-up demand for elective procedures such as the aforementioned treatments.

This dynamic report from Medtech Insight includes analyses of products, markets, competitors, emerging technology and opportunities. Covered products include leading benign uterine therapy devices or systems, specifically global endometrial ablation devices, uterine artery embolization systems, hysteroscopes and related products (including new single-insertion hysteroscopic morcellators), and magnetic resonance-guided high-intensity focused ultrasound systems for treating fibroids.

TABLE OF CONTENTS:
EXECUTIVE SUMMARY

i. Overview of Benign Uterine Conditions and Therapies 
ii. Combined Market Forecast 
iii. Methodology 

Exhibit ES-1: U.S. Benign Uterine Conditions Therapy Systems, Combined Market Forecast, 2012-2017 
Exhibit ES-2: U.S. Benign Uterine Conditions Therapy Systems, Market Forecast, by Product Segment, 2012-2017 

1. OVERVIEW OF TREATMENTS FOR BENIGN UTERINE CONDITIONS

1.1 Dilation and Curettage 
	1.1.1 Procedure Volumes 
1.2 Hysterectomy 
	1.2.1 Procedure Volumes 
1.3 Hysteroscopy 
	1.3.1 Endometrial Ablation 
	1.3.2 Procedure Volumes 
1.4 Myomectomy 
	1.4.1 Procedure Volumes 

Exhibit 1-1: Dilation and Curettage, Procedure Volumes Forecast, 2012-2017 
Exhibit 1-2: Hysterectomy, Procedure Volumes Forecast, 2012-2017 
Exhibit 1-3: Hysteroscopy, Procedure Volumes Forecast, 2012-2017 
Exhibit 1-4: Myomectomy, Procedure Volumes Forecast, 2012-2017 

2. GLOBAL ENDOMETRIAL ABLATION DEVICES

2.1 Selected Products 
	2.1.1 Boston Scientific 
	2.1.2 CooperSurgical/The Cooper Companies 
	2.1.3 Ethicon/Johnson & Johnson 
	2.1.4 Hologic 

Exhibit 2-1: 2013, Leading Global Endometrial Ablation Products 
Exhibit 2-2: Three-Step Endometrial Ablation Using the Genesys Hydro ThermAblator System 
Exhibit 2-3: The Her Option Cryoablation System 
Exhibit 2-4: The Gynecare ThermaChoice III Uterine Balloon Therapy System in Comparison with Other Thermal Ablation Systems 
Exhibit 2-5: The NovaSure System and Step-by-Step Endometrial Ablation Process 
Exhibit 2-6: Selected Features of the Next-Generation NovaSure System 

3. MAGNETIC RESONANCE-GUIDED HIGH-INTENSITY FOCUSED ULTRASOUND SYSTEMS

3.1 Products and Procedure 
	3.1.1 InSightec 
		3.1.1.1 Clinical Trials 
	3.1.2 Philips Healthcare/Royal Philips Electronics 
		3.1.2.1 Clinical Trials 

Exhibit 3-1: Simple Schematic Illustration of Focused Thermal Energy Technology 
Exhibit 3-2: Uterine Fibroid Treatment Using the ExAblate System 
Exhibit 3-3: Sonalleve Therapy 

4. UTERINE ARTERY EMBOLIZATION SYSTEMS

4.1 Selected Products 
	4.1.1 Biocompatibles/BTG International 
	4.1.2 Boston Scientific 
	4.1.3 CeloNova BioSciences 
	4.1.4 Merit Medical Systems 
4.2 Embolization versus Focused Ultrasound for Fibroid Treatment 

Exhibit 4-1: 2013, Selected Embolic Agents Used in Uterine Artery Embolization 
Exhibit 4-2: CeloNova Biosciences' Embozene Microspheres 
Exhibit 4-3: Merit Medical Systems' Embosphere Microspheres 

5. HYSTEROSCOPES AND RELATED PRODUCTS

5.1 Hysteroscopes and Fibroid Removal Systems 
	5.1.1 Ethicon/Johnson & Johnson 
	5.1.2 Gyrus ACMI/Olympus 
	5.1.3 Hologic 
	5.1.4 Olympus America/Olympus 
	5.1.5 Smith & Nephew 
	5.1.6 KARL STORZ Endoscopy-America/KARL STORZ 
	5.1.7 Stryker 
	5.1.8 Richard Wolf Medical Instruments/Richard Wolf 
5.2 Uterine Manipulators 
	5.2.1 ConMed 
	5.2.2 Cook Medical/Cook Group 
	5.2.3 Cooper Surgical/The Cooper Companies 
5.3 Fluid Management Systems 
	5.3.1 Davol/C.R. Bard 
	5.3.2 Gyrus ACMI/Olympus 
	5.3.3 Hologic 
	5.3.4 Smith & Nephew 
	5.3.5 Stryker 
	5.3.6 Richard Wolf Medical Instruments/Richard Wolf 

Exhibit 5-1: 2013, Selected Hysteroscopes and Hysteroscopy Fibroid Removal Systems 
Exhibit 5-2: The Gynecare Versapoint Bipolar Electrosurgery System 
Exhibit 5-3: The Gynecare Morcellex Tissue Morcellator 
Exhibit 5-4: The Gynecare Versascope Hysteroscopy System 
Exhibit 5-5: The PKS PlasmaSORD Bipolar Morcellator 
Exhibit 5-6: The SlimLine Office and USA Series Continuous Flow Operative Hysteroscopes 
Exhibit 5-7: The MyoSure Tissue Removal System 
Exhibit 5-8: The HYF-XP Flexible Hysteroscope 
Exhibit 5-9: The Truclear Hysteroscopic Morcellator 
Exhibit 5-10: The Bettocchi Integrated Office Hysteroscope 
Exhibit 5-11: The Intra-Uterine Bigatti Shaver 
Exhibit 5-12: The Rotocut G1 Morcellator 
Exhibit 5-13: The IDEAL EYES HD CST-5000S Flexible Video Hysteroscope 
Exhibit 5-14: The OptiFLOW Single Sheath Hysteroscope 
Exhibit 5-15: The BipoTrode Bipolar Electrode 
Exhibit 5-16: The VCare Vaginal-Cervical Ahluwalia Retractor/Elevator 
Exhibit 5-17: The Uterine Manipulator Injector 
Exhibit 5-18: The RUMI Advanced Uterine Manipulation System 
Exhibit 5-19: The AquaSens Fluid Monitoring System 
Exhibit 5-20: The Dolphin II Hysteroscopic Fluid Management System 
Exhibit 5-21: The Aquilex Fluid Control System 
Exhibit 5-22: The Hysteroscopic Fluid Management System for Hysteroscopic Morcellation 
Exhibit 5-23: The FluidSafe Fluid Management System 

6. U.S. BENIGN UTERINE CONDITIONS THERAPY SYSTEMS MARKET

6.1 Global Endometrial Ablation Devices 
	6.1.1 Market Forecast 
	6.1.2 Competitive Analysis 
6.2 Uterine Artery Embolization Systems 
	6.2.1 Market Forecast 
	6.2.2 Competitive Analysis 
6.3 Hysteroscopes and Related Products 
	6.3.1 Market Forecast 
	6.3.2 Competitive Analysis 
	6.3.3 Single-Insertion Hysteroscopic Morcellator Systems 
		6.3.3.1 Market Forecast 
		6.3.3.2 Competitive Analysis 
6.4 Combined Market Forecast 

Exhibit 6-1: Global Endometrial Ablation Devices, Market Forecast, 2012-2017 
Exhibit 6-2: 2012, Global Endometrial Ablation Device Market, Share by Supplier 
Exhibit 6-3: Uterine Artery Embolization Systems, Market Forecast, 2012-2017 
Exhibit 6-4: 2012, Uterine Artery Embolization Systems Market, Share by Supplier 
Exhibit 6-5: Hysteroscopes and Related Products, Market Forecast, 2012-2017 
Exhibit 6-6: 2012, Hysteroscopes and Related Products Market, Share by Supplier 
Exhibit 6-7: Single-Insertion Hysteroscopic Morcellator Systems, Market Forecast, 2012-2017 
Exhibit 6-8: 2012, Single-Insertion Hysteroscopic Morcellator Systems Market, Share by Supplier 
Exhibit 6-9: U.S. Benign Uterine Conditions Therapy Systems, Combined Market Forecast, 2012-2017 
Exhibit 6-10: U.S. Benign Uterine Conditions Therapy Systems, Market Forecast, by Product Segment, 2012-2017 
Exhibit 6-11: 2012, U.S. Benign Uterine Conditions Therapy Systems Market,  Share of Sales, by Product Segment 
Exhibit 6-12: 2017, U.S. Benign Uterine Conditions Therapy Systems Market,  Share of Sales, by Product Segment 

7. COMPANY PROFILES

7.1 Boston Scientific Corporation 
7.2 CeloNova Biosciences, Inc. 
7.3 Hologic, Inc. 
7.4 InSightec LTD/Elbit Imaging LTD 
7.5 Johnson & Johnson 
7.6 Philips Healthcare/Royal Philips Electronics NV 
7.7 Smith & Nephew PLC 
7.8 KARL STORZ GmbH & Co. KG 


APPENDIX:  COMPANY LISTING


COMPANIES COVERED:

  1. Biocompatibles International PLC/BTG International LTD
  2. Boston Scientific Corporation
  3. CeloNova BioSciences, Inc.
  4. ConMed Corporation
  5. Cook Medical, Inc./Cook Group, Inc.
  6. CooperSurgical, Inc./The Cooper Companies, Inc.
  7. Davol, Inc./C.R. Bard, Inc.
  8. Ethicon, Inc./Johnson & Johnson
  9. Gyrus ACMI, Inc./Olympus Corporation
  10. Hologic, Inc.
  11. InSightec LTD/Elbit Imaging LTD
  12. Merit Medical Systems, Inc.
  13. Olympus America, Inc./Olympus Corporation
  14. Philips Healthcare/Royal Philips Electronics NV
  15. Smith & Nephew PLC
  16. KARL STORZ Endoscopy-America, Inc./KARL STORZ GmbH & Co. KG
  17. Stryker Corporation
  18. Richard Wolf Medical Instruments Corporation/Richard Wolf GmbH
Contact Us

Need help finding medtech research? Let us help you!